2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors
- PMID: 28561228
- DOI: 10.1055/s-0043-103086
2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors
Abstract
The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Most low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise patient characterization at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials.
© Georg Thieme Verlag KG Stuttgart · New York.
Conflict of interest statement
Conflict of interest: The authors have no conflict of interest to disclose.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
